Start here if you're new
what it is
Biomerica makes medical tests that spot disease and food problems from blood, urine, nasal, or stool samples.
how it gets paid
Last year Biomerica made $5M in revenue.
why growth slowed
Revenue fell 1.9% last year. The $3M quarter mattered because it was 114% higher than a year earlier.
what just happened
Biomerica posted $3M in quarterly revenue, while EPS stayed at -$0.48.
At a glance
C+ balance sheet — struggling to keep the lights on
55/100 earnings predictability — expect surprises
-$2.16 fy2025 eps est
$2B fy2026 rev est
96.7% operating margin
xvary composite: 30/100 — weak
What they do
Biomerica makes medical tests that spot disease and food problems from blood, urine, nasal, or stool samples.
Biomerica sells niche tests through doctors' offices, drugstores, online, and hospital labs. That spread matters for a 54-person company. A small team can still move product when each test solves one narrow problem.
How they make money
$5M
annual revenue · revenue declined -1.9% last year
total revenue
$5M
1.9%
The products that matter
diagnostic-guided IBS test
inFoods® IBS
59.4% symptom improvement
A real-world analysis showed 59.4% of patients experienced symptom improvement. That's the commercial pitch — the harder part is turning clinical interest into revenue.
lead product
H. pylori rapid test
hp+detect™
MHRA registered · mar 2026
The test received UK MHRA registration in March 2026. That opens a real market, but approvals only matter if they start showing up in sales from a $5M revenue base.
new market access
contract manufacturing
CDMO Services
$1.2M · 24% of revenue
This segment contributed $1.2M, or 24% of revenue. It adds some diversification, but with margins undisclosed, you cannot assume it is the part saving the story.
revenue ballast
Key numbers
96.7%
operating margin
You are paying for a business that keeps almost every sales dollar for costs.
$5M
annual revenue
That is the whole top line for the year. It is tiny for a public company.
18.4%
gross margin
After product cost, only 18.4 cents stay from each sales dollar.
54
employees
A 54-person staff has to do everything with very little cushion.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for BMRA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Biomerica posted $3M in quarterly revenue, while EPS stayed at -$0.48.
Revenue was up 114% from a year earlier. Gross margin was 18.4%, which is too thin for a company with operating margin at -96.7%.
$3M
revenue
-$0.48
eps
18.4%
gross margin
the number that mattered
The $3M quarter mattered because it was 114% higher than a year earlier, yet losses still remained.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is cash burn outrunning commercialization of inFoods® IBS and hp+detect™.
med
cash runway stays short
Operating cash flow was -$2.97M against a $2.54M cash balance. In plain English: if spending stays near this pace, the company needs either faster sales or fresh capital.
That pressure hits the entire business, not one product line.
med
clinical traction does not become commercial traction
inFoods® IBS showed 59.4% symptom improvement in a real-world analysis. Good data helps. It does not guarantee physician adoption, reimbursement, or repeat demand.
If the lead product stalls, the path from $5M revenue to profitability gets pushed further out.
med
new approvals arrive before revenue does
hp+detect™ received MHRA registration in March 2026. That is an access milestone, not a revenue milestone. A tiny company can collect approvals and still fail at distribution.
More registrations without sales would add headlines, not cash.
med
another financing event hurts existing holders
The 1-for-8 reverse split in April 2025 already tells you this is a capital-structure story as much as a product story. Small caps with thin liquidity do not raise money on generous terms.
If dilution shows up before revenue inflects, your ownership slice gets smaller before the business gets better.
A -90.3% net margin on $5M of revenue means the company is not solving a valuation problem yet. It is solving an operating problem.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Q3 FY2026 results
Expected around April 13, 2026. The real question is simple: did revenue move above the current $5M annual base, or are launches still mostly a story?
commercial
diagnostic revenue line
Diagnostic products were $3.8M and declined 2.5% last year. You want that number turning up before you trust the commercialization narrative.
liquidity
cash versus burn
$2.54M of cash against -$2.97M of operating cash flow is the scoreboard. If that gap does not narrow, financing risk stays front and center.
execution
post-approval follow-through
After the March 2026 MHRA registration for hp+detect™, the next step is not another press release. It is evidence that distribution is turning access into sales.
Analyst rankings
earnings predictability
55 / 100
Middle of the pack on predictability. In human-speak, the business is small enough that one contract, one delay, or one expense line can swing the quarter.
beta
1.3
Beta measures how much a stock tends to move versus the market. At 1.3, BMRA has historically moved more than the index. Not a bunker stock.
source: institutional data
Institutional activity
institutional ownership data for BMRA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive